Proiectul CLL-CLUE în care participă și echipa Syreon este prezentată la pagina 4
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Europe and it remains incurable. Targeted therapies have revolutionized the treatment of CLL. However, many patients develop resistance, have severe side effects or relapse during treatment.
